<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01605305</url>
  </required_header>
  <id_info>
    <org_study_id>FOLFOX6-2008</org_study_id>
    <nct_id>NCT01605305</nct_id>
  </id_info>
  <brief_title>Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer</brief_title>
  <official_title>Phase II Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to explore whether FOLFOX6 as treatment could improve the time to&#xD;
      progression (TTP) and overall survival (OS) of the patient with recurrent or metastatic&#xD;
      esophagus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Explore whether FOLFOX6 as treatment could improve the TTP and OS of the patient with&#xD;
      recurrent or metastatic esophagus&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TPP</measure>
    <time_frame>from the first cycle of treatment (day one) to two month after the last cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from the first cycle of treatment (day one) to two month after the last cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>FOLFOX6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX6</intervention_name>
    <description>OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h</description>
    <arm_group_label>FOLFOX6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven primary thoracic esophageal squamous cell carcinoma&#xD;
&#xD;
          2. Without chemotherapy or neo-adjuvant chemotherapy in 6 weeks ,radiotherapy has end at&#xD;
             least 1 month,target lesion was not in an irradiated area.&#xD;
&#xD;
          3. Presence of at least one index lesion measurable by CT scan or MRI&#xD;
&#xD;
          4. 18~75 years&#xD;
&#xD;
          5. kps ≥ 70&#xD;
&#xD;
          6. Life expectancy of ≥ 3 months&#xD;
&#xD;
          7. ANC ≥ 2×109/L，PLT ≥ 100×109/L，Hb ≥ 90g/L&#xD;
&#xD;
          8. Cr ≤ 1.0×UNL&#xD;
&#xD;
          9. TB ≤ 1.25×UNL； ALT/AST ≤ 2.5×UNL，THE patient with liver metastasis ALT/AST ≤&#xD;
             5.0×UNL；AKP ≤ 2.5×UNL&#xD;
&#xD;
         10. Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous exposure to oxa therapy in one year&#xD;
&#xD;
          2. diameter of tumor abdominal ≥ 10cm, Total volumes of liver lesions ≥ 50%,lung&#xD;
             metastasis ≥ 25% total lung&#xD;
&#xD;
          3. chronic diarrhea,enteritis,intestine obstruction which are not under control&#xD;
&#xD;
          4. Psychiatric or addictive disorders that preclude obtaining informed consent or&#xD;
             adherence to protocol.&#xD;
&#xD;
          5. peripheral neuropathy ≥ CTCAE 1&#xD;
&#xD;
          6. Other serious disease&#xD;
&#xD;
          7. Previous or concomitant malignancies except non-melanoma skin cancer, carcinoma in&#xD;
             situ of the cervix, and invasive carcinoma of the colon, thyroid, cervix, or&#xD;
             endometrium treated five years prior to study entry.&#xD;
&#xD;
          8. USE OTHER ANTITUMOR THERAPY&#xD;
&#xD;
          9. Breast-feeding or pregnant women, no effective contraception if risk of conception&#xD;
             exists&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chang j h, post-doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>May 22, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2012</study_first_posted>
  <last_update_submitted>May 23, 2012</last_update_submitted>
  <last_update_submitted_qc>May 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Chang Jian Hua</investigator_full_name>
    <investigator_title>associate chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

